Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While GHK-Cu acts as a tissue-remodeling and wound-healing signal, enhancing skin regeneration, angiogenesis, and repair while reducing inflammation and oxidative damage in experimental models31383, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While GHK-Cu works as an endogenous tripeptide, Gly-His-Lys, that chelates Cu²⁺ and modulates gene expression, stimulating collagen, elastin, proteoglycan, and glycosaminoglycan synthesis while exerting antioxidant and anti-inflammatory effects31383, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
GHK-Cu
Not assigned in the current dataset.
Liraglutide
GCG
GHK-Cu and Liraglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: GHK-Cu is more often discussed in the realm of Dermatology and aesthetics and Aging and longevity, whereas Liraglutide is more often associated with the realm of Metabolic and endocrine. They also influence different molecular systems, with GHK-Cu tracking more closely to Extracellular matrix proteins while Liraglutide centers more on GLP-1 receptor. GHK-Cu has a more natural endogenous origin, while Liraglutide is closer to synthetic analog background and their development context also differs, with GHK-Cu cosmetic grade while Liraglutide is approved. Liraglutide incorporates palmitoylation features that are not part of GHK-Cu, while their sequence patterns also diverge, with GHK-Cu showing protein-mimetic sequence features and Liraglutide showing alpha-helical domain features.